Exact Mass: 512.0491396
Exact Mass Matches: 512.0491396
Found 72 metabolites which its exact mass value is equals to given mass value 512.0491396,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
6-(Dibromomethylene)-17beta-hydroxy-androst-4-en-3-one propionate
Cefamandole nafate
C19H17N6NaO6S2 (512.0548662000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid
{2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid
3,5,7-Trihydroxyflavone 3-glucoside-8-sulfate
apigenin 7-beta-D-glucopyranosyl-2-sulfate|thalassiolin C
7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,2,6,8-tetrol
alpha-Oxo-2,4,6-trihydroxy-3-[2-(3,4-dihydroxyphenyl)-4-oxo-5,7-dihydroxy-2,3-epoxy-3,4-dihydro-2H-1-benzopyran-3-yl]benzeneacetic acid methyl ester
Peracetate Quercetin
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.197 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.201
PU-H71
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents
3,3-diethyl-2,2-oxathiacarbocyanine iodide
C25H25IN2O2 (512.0960699999999)
bis-(2,4,6-Trimethylpyridine)iodine(I) hexafluorophosphate
C16H20F6IN2P (512.0312991999999)
2-CHLORO-N-(2-(PYRIDIN-3-YLAMINO)PYRIMIDIN-5-YL)-5-(3-(TRIFLUOROMETHYL)BENZAMIDO)BENZAMIDE
2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile
Cromolyn sodium
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C29714 - Mast Cell Stabilizer COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000893 - Anti-Inflammatory Agents > D000082142 - Mast Cell Stabilizers D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents D018926 - Anti-Allergic Agents D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Trovafloxacin Mesylate
C21H19F3N4O6S (512.0977350000001)
A methanesulfonate (mesylate) salt prepared from equimolar amounts of trovafloxacin and methanesulfonic acid. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors
3-(Perfluoro-5-methylhexyl)-2-hydroxypropyl methacrylate
C14H11F15O3 (512.0468635999999)
5-Chloro-4-((1-(5-chloro-2-pyrimidinyl)-4-piperidinyl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)-2(1H)-pyridinone
dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-hexopyranose
5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol
3-D-glucosyluronate-N2-,6-disulo-beta-D-glucosamine
C12H18NO17S2-3 (512.0016158000001)
2-[(2-Hydroxynaphthalen-1-yl)diazenyl]-5-[(4-sulfophenyl)diazenyl]benzene-1-sulfonic acid
N-[4-[[3-(4-sulfamoylanilino)-2-quinoxalinyl]sulfamoyl]phenyl]acetamide
N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide
N-[1-benzyl-2,4,6-trioxo-5-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl]-2,4-dichlorobenzamide
3-D-glucuronosyl-N(2),6-disulfonato-beta-D-glucosamine(3-)
C12H18NO17S2-3 (512.0016158000001)
(4-{(E)-[5-(4-chlorophenyl)-6-(ethoxycarbonyl)-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2(3H)-ylidene]methyl}phenoxy)acetic acid
ustilaginoidin A(2-)
A phenolate anion that is the conjugate base of ustilaginoidin A, obtained by deprotonation of the two hydroxy groups at positions 5 and 5. It is the major microspecies at pH 7.3.
dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose(2-)
A nucleotide-sugar oxoanion arising from deprotonation of the diphosphate OH groups of dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose; major species at pH 7.3.
GSK-25
GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1].
(1r,3s,4s,7r,8s,12s,13s)-3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-5-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
(1r,3s,4r,7r,8s,12s,13r)-3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-5-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
(1r,3s,4r,7r,8s,12s,13s)-3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-5-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
(1s,2s,3r,11r,14s)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione
methyl 9-[(1s)-1-(acetyloxy)ethyl]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate
3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-5-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione
methyl 9-[1-(acetyloxy)ethyl]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxotetraphene-10-carboxylate
(2r)-2,3-bis(formyloxy)propoxy(3-{[(2r)-2,3-bis(formyloxy)propoxy(hydroxy)phosphoryl]oxy}-2-hydroxypropoxy)phosphinic acid
C13H22O17P2 (512.0332222000001)
(1r,3s,6s,7r,8s,12s,13s)-3,6,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-4-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
(5-hydroxy-7-methyl-9,10-dioxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid
(5-hydroxy-7-methyl-9,10-dioxo-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}anthracen-2-yl)oxidanesulfonic acid
3,6,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-4-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)
methyl 2-{3-[3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate
methyl 2-{3-[(3r)-3-(3,4-dihydroxyphenyl)-8,10-dihydroxy-6-oxo-2,4-dioxatricyclo[5.4.0.0³,⁵]undeca-1(11),7,9-trien-5-yl]-2,4,6-trihydroxyphenyl}-2-oxoacetate
(1s,2s,3r,11r,14r)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione
(3z)-7,16,18-trichloro-11,22-dihydroxy-4,19,19-trimethyl-8-methylidene-20-oxatetracyclo[11.7.1.1¹⁰,¹⁴.0¹,¹⁶]docosa-3,10,12,14(22)-tetraene-15,21-dione
7-(3,5-dihydroxyphenoxy)-3-(2,4,6-trihydroxyphenoxy)oxanthrene-1,2,6,8-tetrol
5,7-dihydroxy-4-oxo-2-phenyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}chromene-8-sulfonic acid
(1r,3s,6r,7r,8s,12s,13s)-3,6,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-17-methyl-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.0¹,¹⁰.0³,⁸]heptadec-4-ene-11,16-dione
C21H24N2O9S2 (512.0923174000001)